4Michael M, Elliott E J, Ridley G F, et al. Interventions for haernolytic uraemic syndrome and thrombotic thrombocytopcnic purpura[J]. Cochrane Database Syst Rev, 2009, 21 (1) : CD003595.
9Tsai HM, Raoufi M, Zhou W, et al. ADAMTS13 - binding IgG are present in patients with thrombotic thrombocytopenic purpura[J].Thromb Haemost, 2006, 95(5): 886.
4Tsai HA.Advances in the pathogenesis,diagnosis,and treatment of Thrombotic thrombocytopenic purpura[J].Jam Soc Nephrol,2003,14(3):1072.
5Patton JF,Manning KR,Case D,et al.Serum lactate dehydrogenase and platelet count predict survival in thrombotic thrombocytopenic purpura[J].Am J of Hematol,1994,47(2):94.
6Vesely SK,Ceorge JN,Lammle B,et al.ADAMTS13 activity inthrombotic thrombocytopenic purpura-hemolytic uremic syndrome:relation to presenting features and clinical outcomes in a prospective cohort of 142 patients[J].Blood,2003,102:60-68.
7Zheng XL,Kaufman RM,Goodnough LT,et al.Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity,inluhitor level,and clinical outcome in patients with idiopathic and nonidiopathic thromhotic thromhocytopenic purpura[J].Blood,2004,103:4043-4049.
8Fakhouri F,Vemant JP,Veyradier A,et al.Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thromhotic thrombocytopenic purpura:a study of ll cases[J].Blood JT Blood,2005,106:1932-1937.
9Fakhouri F,Deroure B,Hummel A.A new treatment for TTP[J].Nephrol Dial Transplant,2600,21:577-579.
5Jin M, Casper T C, Cataland S R, et al. Relationship be- tween ADAMTS13 activity in clinical remission and the risk of ITP relapse[ J]. Br J Haematol, 2008,141 (5) :651-658.
6Crowther M A, George J N. Thrombotic thrombocytopenic purpura: 2008 update[J]. Cleve Clin J Med, 2008,75(5): 369-375.
7Frawley N, Ng A P, Nicholls K, et al. Thrombotic thrombo- cytopenic purpura is associated with a high relapse rate after plasma exchange : a single-centre experience[ J 1. Intern Med J, 2009,39(1) :19-24.
8Aqui N A, Stein S H, Konkle B A, et al. Role of splenecto- my in patients with refractory or relapsed thrombotic throm- bocytopenic purpura[J]. J Clin Apher, 2003,18(2):51-54.
9Bucciarelli S, Cervera R, Espinosa G, et al. Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors [ J ]. Autoimmun Rev, 2006,6 (2) :72-75.
10Asherson R A. The catastrophic antiphospholipid (Asherson's) syndrome [ J ]. Autoimmun Rev, 2006,6 (2) :64-67.
